GlassScriptPhysician profile
Bruce Warren Usher
NPI 1669470191
$6,850.41
in general payments reported to CMS, 2019-2025
26 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $256 · 2021: $707 · 2022: $1,752 · 2023: $2,545 · 2024: $653 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,621 · Travel and Lodging: $1,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,620.91 |
| Travel and Lodging | $1,301.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,976.33 | 2021-2025 | Watchman Access System, Watchman Flx, General - Ep |
| Medtronic, INC. | $1,290.79 | 2022 | |
| Esperion Therapeutics, INC. | $647.63 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $454.39 | 2019-2025 | Jardiance |
| Irhythm Technologies, INC. | $193.71 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.98 | 2021-2025 | Lifevest |
| Atricure, INC. | $151.65 | 2025 | Atricure Cryoice Cryosphere Cryoablation System, Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Novartis Pharmaceuticals Corporation | $136.45 | 2019-2025 | |
| Amgen INC. | $127.17 | 2024-2025 | Repatha, Repatha |
| Celgene Corporation | $114.46 | 2022-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $113.95 | 2019-2023 | Farxiga |
| Abiomed | $92.86 | 2025 | |
| Janssen Pharmaceuticals, INC | $67.28 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $62.87 | 2023 | Opsumit, Uptravi |
| Novo Nordisk INC | $56.43 | 2024-2025 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $37.18 | 2021-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $34.59 | 2024 | Winrevair |
| Lantheus Medical Imaging, INC. | $23.13 | 2025 | |
| Impulse Dynamics (USA) INC. | $18.97 | 2023 | Optimizer |
| Lundbeck LLC | $17.97 | 2019 | |
| Pfizer INC. | $17.08 | 2024 | |
| Phathom Pharmaceuticals, INC. | $15.22 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $13.72 | 2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $13.70 | 2019 | |
| Altathera Pharmaceuticals LLC | $11.90 | 2025 | Sotalol Hydrochloride |
| Bardy Diagnostics, INC. | $5.00 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Usher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.